Differential involvement of μ-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception

European Journal of Pharmacology

Volumn 372, Issue 1, 1999, Pages 25-30

  Sakurada, Shinobu ^a   Zadina, James E ^b   Kastin, Abba J ^b   Katsuyama, Sou ^a   Fujimura, Tsutomu ^c   Murayama, Kimie ^c   Yuki, Masayuki ^a   Ueda, Hiroshi ^d   Sakurada, Tsukasa ^e  

^a Tohoku Pharmaceutical U ^*  (Japan)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JUNTENDO UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

Funaltrexamine; Endomorphin 1; Endomorphin 2; Naloxonazine; Tail pressure test

Indexed keywords

BETA FUNALTREXAMINE; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU 1 OPIATE RECEPTOR; MU 1 OPIATE RECEPTOR ANTAGONIST; MU 2 OPIATE RECEPTOR; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONAZINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; MALE; MECHANICAL STIMULATION; MOUSE; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALINS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MICE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTORS; OLIGOPEPTIDES; PAIN; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 0032893243     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00181-8     Document Type: Article

References (22)

1. 2-adrenoceptors. Eur. J. Pharmacol. 298:1996;235-239.
2. Goldberg I.E., Rossi G.C., Letchworth S.R., Mathis J.P., Ryan-Moro J., Leventhal L., Su W., Emmel D., Bolan E.A., Pasternak G.W. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J. Pharmacol. Exp. Ther. 286:1998;1007-1013.
3. Goodman R.R., Pasternak G.W. Visualization of mu-1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique. Proc. Natl. Acad. Sci. USA. 82:1985;6667-6671.
4. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
5. Heyman J.S., Williams C.L., Burks T.F., Mosberg H.I., Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse; studies with naloxonazine. J. Pharmacol. Exp. Ther. 245:1988;238-243.
6. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 67:1980;313-316.
7. Irwin S., Houde R.W., Bennett D.R., Hendershot L.C., Seevers M.H. The effect of morphine, methadone and meperidine on some reflex responses of spinal animals to nociceptive stimulation. J. Pharmacol. Exp. Ther. 10:1951;132-143.
8. Ling G.S.F., Simantov R., Clark J.A., Pasternak G.W. Naloxonazine action in vivo. Eur. J. Pharmacol. 129:1986;33-38.
9. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
10. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature. 383:1996;819-823.
11. 3H -opioid binding: further evidence for mu sites Mol. Pharmacol. 25:1984;29-37.
12. Pasternak G.W., Wood P.L. Multiple mu opiate receptors. Life Sci. 38:1986;1888-1898.
13. Paul D., Bodnar R.J., Gistrak M.A., Pasternak G.W. Different μ receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmacol. 168:1989;307-314.
14. 2 opioid actions. Life Sci. 48:1991;2005-2011.
15. Recht L.D., Pasternak G.W. Effects of β-funaltrexamine on radiolabeled opioid binding. Eur. J. Pharmacol. 230:1987;341-344.
16. Stone L.S., Fairbanks C.A., Laughlin T.M., Nguyen H.O., Bushy T.M., Wessendorf M.W., Wilcox G.L. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. NeuroReport. 8:1997;3131-3135.
17. Wolozin B.L., Pasternak G.W. A classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. USA. 78:1981;6181-6185.
18. 2). Neurosci. Lett. 155:1993;220-222.
19. Zadina J.E., Kastin A.J., Ge L.-J., Hackler L. Mu, delta and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs. Life Sci. 24:1994;PL461-466.
20. 2 opiate receptors. Neurosci. Lett. 215:1996;65-69.
21. Zadina J.E., Hackler L., Ge L.J., Kastin A.J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature. 386:1997;499-502.
22. Zimprich A., Simon T., Hollt V. Cloning and expression of an isoform of the rat μ opioid receptor (rMORIB) which differs in a agonist induced desensitization from rMOR1. FEBS Lett. 359:1995;142-146.